Therapeutic Solutions International (TSOI) 10-K/A 12 Apr 21 2020 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	Apr. 07, 2021	Dec. 31, 2020	Jun. 30, 2020
Details
Registrant CIK		0001419051
Fiscal Year End		--12-31
Document Type		10-K/A
Document Annual Report		true
Document Period End Date		Dec. 31, 2020
Document Transition Report		false
Entity File Number		000-54554
Entity Registrant Name		Therapeutic Solutions International, Inc.
Entity Incorporation, State or Country Code		NV
Entity Tax Identification Number		45-1226465
Entity Address, Address Line One		701 Wild Rose Lane
Entity Address, City or Town		Elk City
Entity Address, State or Province		ID
Entity Address, Postal Zip Code		83525
Entity Address, Address Description		Address of principal executive offices, including zip code
City Area Code		760
Local Phone Number		295-7208
Phone Fax Number Description		Registrant's telephone number, including area code
Entity Well-known Seasoned Issuer		No
Entity Voluntary Filers		No
Entity Current Reporting Status		No
Entity Interactive Data Current		No
Entity Filer Category		Non-accelerated Filer
Entity Small Business		true
Entity Emerging Growth Company		false
Entity Shell Company		false
Entity Public Float			$ 10,568,184
Share Price			$ 0.0076
Entity Common Stock, Shares Outstanding	2,244,453,070
Entity Listing, Par Value Per Share	$ 0.0001
Amendment Flag		false
Document Fiscal Year Focus		2020
Document Fiscal Period Focus		FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 252,147	$ 26,410
Restricted cash	10,202	10,187
Accounts receivable	2,441	2,904
Inventory	5,399	5,180
Prepaid expenses and other current assets	77,328	89,379
Total current assets	347,517	134,060
Property and equipment, net	5,059	0
Right-of-use asset	58,976	5,619
Other Assets	191,922	171,322
Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment	255,957	176,941
Total assets	603,474	311,001
Current liabilities:
Accounts payable	302,477	324,936
Accounts payable-related parties	7,210	12,715
Accrued expenses and other current liabilities	593,925	505,072
Lease liability	24,792	5,619
Convertible notes payable, net of discount of $195,162 and $105,525, at December 31, 2020 and 2019, respectively	37,338	38,475
Notes payable-related parties, net	944,098	937,528
Derivative Liability, Current	437,549	521,700
Total current liabilities	2,347,389	2,346,045
LONG TERM LIABILITIES
Lease liability, net of current portion	34,184	0
TOTAL LIABILITIES	2,381,573	2,346,045
Commitments and contingencies	0	0
Shareholders' deficit:
Preferred shares	0	0
Common shares	2,233,742	1,614,628
Additional paid-in capital	7,041,960	5,183,228
Subscription receivable	(21,000)	0
Accumulated deficit	(11,032,801)	(8,832,900)
Total shareholders' deficit	(1,778,099)	(2,035,044)
Total liabilities and shareholders' deficit	$ 603,474	$ 311,001

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
Debt Instrument, Unamortized Discount, Current	$ 195,162	$ 105,525
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	3,500,000,000
Common Stock, Shares, Issued	2,233,741,391	1,614,627,811
Common Stock, Shares, Outstanding	2,233,741,391	1,614,627,811

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Details
Net sales	$ 62,681	$ 27,495
Cost of goods sold	12,792	3,015
Gross profit	49,889	24,480
Operating Expenses
General and administrative	88,429	70,537
Salaries, wages, and related costs	318,817	305,133
Stock compensation	530,900	355,000
Consulting fees	119,209	181,374
Legal and professional fees	280,124	127,917
Research and development	561,990	27,685
Total operating expenses	1,899,469	1,067,646
Operating Income (Loss)	(1,849,580)	(1,043,166)
Other income (expense):
Loss on derivative liability	(247,620)	(352,934)
Change in fair value of derivative liabilities	206,501	49,521
Interest expense	(302,481)	(350,743)
Other expense	(6,721)	0
Total other income (expense)	(350,321)	(654,156)
Net Income (Loss)	$ (2,199,901)	$ (1,697,322)
Basic and diluted net loss per common share	$ 0	$ 0
Basic and diluted weighted-average common shares outstanding	1,911,855,232	1,284,150,496

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Subscription Receivable	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2018	$ 1,011,063	$ 4,314,047	$ 0	$ (7,135,578)	$ (1,810,468)
Shares, Outstanding, Beginning Balance at Dec. 31, 2018	1,011,063,182
Stock Issued During Period, Value, Issued for Services	$ 200,000	268,000	0	0	468,000
Stock Issued During Period, Shares, Issued for Services	200,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 235,562	526,702	0	0	762,264
Stock Issued During Period, Shares, Conversion of Convertible Securities	235,561,296
Common stock issued for a license, Value	$ 95,970	57,582	0	0	153,552
Common stock issued for a license, Shares	95,970,000
Stock Issued During Period, Value, New Issues	$ 72,033	4,397	0	0	76,430
Stock Issued During Period, Shares, New Issues	72,033,333
Beneficial conversion feature on note payable	$ 0	12,500	0	0	12,500
Net Income (Loss)	$ 0	0	0	(1,697,322)	(1,697,322)
Shares, Outstanding, Ending Balance at Dec. 31, 2019	1,614,627,811
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2019	$ 1,614,628	5,183,228	0	(8,832,900)	(2,035,044)
Stock Issued During Period, Value, Issued for Services	$ 173,500	496,250	0	0	669,750
Stock Issued During Period, Shares, Issued for Services	173,500,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 174,556	528,596	0	0	703,152
Stock Issued During Period, Shares, Conversion of Convertible Securities	174,556,025
Stock Issued During Period, Value, New Issues	$ 192,376	436,124	(21,000)	0	607,500
Stock Issued During Period, Shares, New Issues	192,375,737
Beneficial conversion feature on note payable					0
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture	$ 78,682	417,218	0	0	495,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	78,681,818
Offering costs	$ 0	(19,456)	0	0	(19,456)
Net Income (Loss)	$ 0	0	0	(2,199,901)	(2,199,901)
Shares, Outstanding, Ending Balance at Dec. 31, 2020	2,233,741,391
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2020	$ 2,233,742	$ 7,041,960	$ (21,000)	$ (11,032,801)	$ (1,778,099)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net Income (Loss)	$ (2,199,901)	$ (1,697,322)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants	100,600	113,000
Stock-based compensation to related parties	1,065,050	355,000
Loss on derivative liabilities	247,620	352,934
Change in fair value of derivative liabilities	(206,501)	(49,521)
Gain on extinguishment of debt	(16,479)	0
Amortization of debt discount	251,801	278,593
Patent amortization	6,591	6,591
Depreciation	389	0
Changes in operating assets and liabilities:
Accounts receivable	463	(2,904)
Inventory	(219)	(5,180)
Prepaid expenses and other current assets	(15,140)	60,621
Right-of-use asset	(53,357)	(5,619)
Accounts payable	(22,458)	4,122
Accounts payable - related parties	(5,505)	4,734
Accrued expenses and other current liabilities	130,611	268,618
Lease liability	53,356	5,619
Net cash used in operating activities	(663,079)	(310,714)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5,448)	0
Net cash used in investing activities	(5,448)	0
Cash flows from financing activities:
Payments on notes payable to related party	(25,244)	(3,689)
Proceeds from notes payable to related party	0	25,000
Payments on convertible notes payable	0	(33,000)
Proceeds from convertible notes payable	315,000	250,000
Proceeds from notes payable	16,479	0
Proceeds from sale of common stock	588,044	76,430
Net cash provided by financing activities	894,279	314,741
Net increase (decrease) in cash	225,752	4,027
Cash and cash equivalents	36,597	32,570
Cash and cash equivalents	262,349	36,597
Supplemental disclosure of cash flow information
Cash paid for interest	6,369	21,581
Income Taxes Paid	1,585	0
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable	21,500	0
Debt discount recorded in connection with derivative liability	315,000	250,000
Common stock issued in conversion of convertible notes payable and interest	713,152	762,264
Beneficial conversion feature on note payable	0	12,500
Common stock issued in payment of license agreement	0	153,552
Formalization of accrued salary into related party note	0	430,715
Accrued interest added to principal	26,876	35,614
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	252,147	26,410
Restricted cash included in other assets	10,202	10,187
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows	$ 262,349	$ 36,597

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2020
Notes
Note 1 - Nature of Business	Note 1 – Nature of business Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. Nutraceutical Division Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. Management does not expect existing cash as of December 31, 2020 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2020, the Company has incurred losses totaling $11 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and significant accounting policies	12 Months Ended
	Dec. 31, 2020
Notes
Note 2 - Basis of Presentation and significant accounting policies	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) 2) 3) 4) 5) ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Wholesale policies: Delivery. Purchase Price & Payments. Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Returns. Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. $250,000 cash deposited in the financial institution as of the balance sheet date is insured by the Federal Deposit Insurance Corporation (FDIC) and the amount not insured is $12,147, there isn’t any losses recorded as of December 31, 2020. Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $437,549 and $521,700 at December 31, 2020 and 2019, respectively. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2020 and 2019 was $389 and $0, respectively. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2020 and 2019 was $6,591 and $6,591, respectively. Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $561,990 and $27,685 for the years ended December 31, 2020 and 2019, respectively. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $58,976 as of December 31, 2020. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2020 and 2019, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2020 and 2019: Balance, December 31 $ 466,612 Issuance of new derivative liabilities 602,934 Conversions to paid-in capital (498,325) Change in fair market value of derivative liabilities (49,521) Balance, December 31, 2019 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270) Change in fair market value of derivative liabilities (206,501) Balance, December 31, 2020 $ 437,549 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2020 and 2019, a total of 579,347,525 and 181,588,903 , Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Note 3 - Restricted Cash

Note 3 - Restricted Cash	12 Months Ended
	Dec. 31, 2020
Notes
Note 3 - Restricted Cash	Note 3 – Restricted cash Included in current assets is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2021, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Note 4 - Prepaid expense and ot

Note 4 - Prepaid expense and other current assets	12 Months Ended
	Dec. 31, 2020
Notes
Note 4 - Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: December 31, 2020 December 31, 2019 Prepaid consulting $ 76,663 $ 88,261 Insurance 665 - Prepaid costs - 1,118 Total $ 77,328 $ 89,379

Note 5 - Fixed assets

Note 5 - Fixed assets	12 Months Ended
	Dec. 31, 2020
Notes
Note 5 - Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: December 31, 2020 December 31, 2019 Computer hardware $ 10,747 $ 10,747 Office furniture and equipment 3,639 3,639 Shipping and other equipment 7,023 1,575 Total 21,409 15,961 Accumulated depreciation (16,350) (15,961) Property and equipment, net $ 5,059 $ - Depreciation expense was $389 and $0 for December 31, 2020 and 2019, respectively.

Note 6 - Other Assets

Note 6 - Other Assets	12 Months Ended
	Dec. 31, 2020
Notes
Note 6 - Other Assets	Note 6 – Other assets Other assets consist of the following: December 31, 2020 December 31, 2019 Prepaid consulting $ 39,914 $ 20,238 Deposit 11,638 4,123 Licenses, net 140,370 146,961 Total $ 191,922 $ 171,322 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: December 31, 2020 December 31, 2019 License $ 153,552 $ 153,552 Accumulated amortization (13,182) (6.591) Licenses, net $ 140,370 $ 146,961 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.

Note 7 - Convertible Notes Paya

Note 7 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Notes
Note 7 - Convertible Notes Payable	Note 7 – Convertible notes payable On January 2, 2019, February 7, 2019, March 11, 2019, April 23, 2019, August 28, 2019, October 30, 2019 and December 13, 2019, the Company entered into two $28,000 convertible promissory notes, three $33,000 convertible promissory notes, one $78,000 convertible promissory note and one $38,000 convertible promissory note with a third party for which the proceeds were used for operations. The Company received net proceeds of $250,000 and a $21,000 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum for which $28,000 plus accrued interest are due on January 30, 2020 and October 30, 2020 and $33,000 plus accrued interest are/were due October 30, 2019, November On various dates throughout the year ended December 31, 2020, the Company entered into seven convertible promissory notes with principal amounts totaling $336,500 with a third party for which the proceeds were used for operations. The Company received net proceeds of $315,000, and a $21,500 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum and mature on dates ranging from February 3, 2021 to December 17, 2021. The convertible promissory notes are convertible to shares of the Company's common stock 180 days after issuance. The conversion price per share is equal to 61% of the average of the three (3) lowest trading prices of the Company's common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2020 a total of 579,347,525 common shares in connection with these promissory notes. Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the seven notes issued during the year ended December 31, 2019, the Company valued the conversion feature on the date of issuance resulting in initial liability of $602,934. Since the fair value of the derivatives were in excess of the proceeds received of $250,000, a full discount to convertible notes payable and a day one loss on derivative liabilities of $352,934 was recorded during the year ended December 31, 2019. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.001 to $0.003, the closing stock price of the Company's common stock on the date of valuation ranging from $0.002 to $0.009, an expected dividend yield of 0%, expected volatility ranging from 236% to 262%, risk-free interest rates ranging from 1.55% to 2.60%, and an expected term ranging from 0.81 to 1 years. During the year ended December 31, 2019, three of the $28,000 convertible notes and five of the $33,000 convertible notes were converted into 235,561,296 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2019, the Company recorded a gain of $310,347 related to the change of fair value of the derivative liability and recorded $498,324 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0004 to $0.002, the closing stock price of the Company's common stock on the date of valuation ranging from $0.001 to $0.009, an expected dividend yield of 0%, expected volatility ranging from 214% to 263%, risk-free interest rates ranging from 1.56% to 2.59%, and expected terms ranging from 0.26 to 0.38 years. On December 31, 2019, the derivative liabilities on the remaining three convertible notes were revalued at $521,700 resulting in a loss of $260,826 for the year ended December 31, 2019 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.001, the closing stock price of the Company's common stock on the date of valuation of $0.003, an expected dividend yield of 0%, expected volatility ranging from 245% to 262%, risk-free interest rate of 1.59%, and an expected term ranging from 0.5 to 0.95 years. For the seven notes issued during the year ended December 31, 2020, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $562,620. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $247,620 was recorded during the year ended December 31, 2020. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0008 to $0.0042, the closing stock price of the Company's common stock on the dates of valuation ranging from $0.0023 to $0.0056, an expected dividend yield of 0%, expected volatilities ranging from 237%-260%, risk-free interest rate ranging from 0.17% to 1.48%, and an expected term of one year. During the year ended December 31, 2020, convertible notes principal plus their accrued interest totaling $262,881 were converted into 174,556,025 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2020, the Company recorded $440,270 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.00055 to $0.0039, the closing stock price of the Company's common stock on the dates of valuation ranging from $0.001 to $0.010, an expected dividend yield of 0%, expected volatility ranging from 170% to 305%, risk-free interest rates ranging from 0.12% to 0.89%, and expected terms ranging from 0.07 to 0.50 years. On December 31, 2020, the derivative liabilities on the remaining four convertible notes were revalued at $437,539 resulting in a gain of $206,501 for the year ended December 31, 2020 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.0029, the closing stock price of the Company's common stock on the date of valuation of $0.0064, an expected dividend yield of 0%, expected volatility ranging from 241% to 254%, risk-free interest rate of 0.12%, and an expected term ranging from 0.76 to 0.96 years. The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2020 and 2019, the Company amortized $251,801 and $278,593 to interest expense, respectively. As of December 31, 2020, discounts of $195,162 remained for which will be amortized through December 2021.

Note 8 - Notes Payable - Relate

Note 8 - Notes Payable - Related Parties	12 Months Ended
	Dec. 31, 2020
Notes
Note 8 - Notes Payable - Related Parties	Note 8 – Notes payable-related parties Notes payable-related parties consist of: December 31, 2020 December 31, 2019 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 $ 7,054 $ 18,162 Two notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019 26,064 37,671 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,646 534,700 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 112,000 105,600 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004,respectively, with maturity date of April 20, 2019 264,334 246,334 944,098 942,467 Less debt discount - (4,939) $ 944,098 $ 937,528

Note 9 - Related party transact

Note 9 - Related party transactions	12 Months Ended
	Dec. 31, 2020
Notes
Note 9 - Related party transactions	Note 9 – Related party transactions As of December 31, 2020 and 2019, the Company had accrued officers’ salary of $524,034 and $663,100, respectively. One of the officers settled with the company for a note payable that is unsecured and doesn’t accrue interest and will be paid as 0.5% of revenues. This decreased accrued officers’ salary in 2019. On December 12, 2019, we issued 100,000,000 shares of common stock, valued at $0.0013 each to one officer and one director of the Company under a Restricted Stock Award. On June 4, 2020 we issued 70,000,000 shares of common stock, valued at $0.023 each to three officers and one director of the Company under a Restricted Stock Award. On June 9, 2020, the Company settled an accrual of wages with Timothy G. Dixon with a convertible note payable of $60,000 with interest at 5% per annum. On June 9, 2020, we issued 18,181,818 shares of common stock for the complete conversion of $60,000 for convertible note dated June 9, 2020. On June 11, 2020 we issued 40,000,000 shares of common stock, valued at $0.0046 each to three officers and one director of the Company under a Restricted Stock Award. On June 15, 2020 we issued 3,000,000 shares of common stock, valued at $0.0017 each to one officer and one director of the Company under a Restricted Stock Award. On June 15, 2020, we issued 10,000,000 shares of common stock, valued at $0.0023 per share, to the medical officer for consulting services. On June 25, 2020, we issued 10,000,000 shares of common stock, valued at $0.0083 per share, to the medical officer for consulting services. On July 17, 2020 we issued 7,500,000 shares of common stock, valued at $0.0064 each to two officers, and one director of the Company under a Restricted Stock Award. On July 31, 2020 we issued 12,000,000 shares of common stock, valued at .0077 each to three officers, and one director of the Company under a Restricted Stock Award. On October 1, 2020, we issued 15,000,000 shares of common stock, valued at $0.0071 per share, each to two officers, and one director of the Company under a Restricted Stock Award. On October 5, 2020, we issued 10,000,000 shares of common stock, valued at $0.0086 per share each to one officer and one director of the Company under a Restricted Stock Award. On December 17, 2020, we issued 10,000,000 shares of common stock, valued at $0.0067 per share each to one officer and one director of the Company under a Restricted Stock Award. On December 30, 2020, we issued 6,000,000 shares of common stock, valued at $0.006 per share each to one officer and one director of the Company under a Restricted Stock Award.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes
Note 10 - Income Taxes	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2020 December 31, 2019 Expected income tax at statutory rate $ (458,619) $ (356,438) State tax 168 168 Permanent differences 295,578 220,501 Other (336) 6,556 Change in valuation allowance 163,209 129,213 Provision for income taxes $ - $ - The significant components of deferred income tax assets and liabilities at December 31, 2020 and 2019 are as follows: December 31, 2020 December 31, 2019 Net operating loss carry-forward $ 1,668,324 $ 1,450,896 Valuation allowance (1,668,324) (1,450,896) Net deferred tax asset $ - $ - The Company has net operating losses carried forward of approximately $6.5 million and $5.7 million as of December 31, 2020 and 2019, respectively, available to offset taxable income in future years which $5 million expires in 2032 and after 2018, are subject to an 80% on taxable income and carries on indefinitely. As of and for the years ended December 31, 2020 and 2019, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2020 and 2019. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2017. The Company currently is not under examination by any tax authority.

Note 11 - Equity

Note 11 - Equity	12 Months Ended
	Dec. 31, 2020
Notes
Note 11 - Equity	Note 11 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December 31, 2020, we have 2,233,741,391 shares of common stock and no preferred shares issued and outstanding. In 2019, we issued 72,033,333 shares of common stock for an investment in the Company’s Private Placement of $76,430. In 2019, we issued 200,000,000 shares of common stock valued at $468,000 for consulting services. In 2019, we issued 95,970,000 shares of common stock, valued at $153,552 for a licesnse. In 2019, we issued 235,561,296 shares of common stock for the conversion of convertible notes of $762,264. In 2020, we issued 192,375,737 shares of common stock for an investment in the Company’s Private Placement of $607,500. In 2020, we issued 173,500,000 shares of common stock, valued at $669,750 for consulting services. In 2020, we issued 78,681,818 shares of common stock, valued at $495,900 for salaries. In 2020, we issued 174,556,025 shares of common stock for the conversion of convertible notes of $703,152.

Note 12 - Legal proceedings

Note 12 - Legal proceedings	12 Months Ended
	Dec. 31, 2020
Notes
Note 12 - Legal proceedings	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes
Note 13 - Commitments and Contingencies	Note 13 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2023. During the year ended December 31, 2020 and 2019, the Company incurred rent expense of $25,993 and $22,494. Future minimum lease payments as of December 31, 2020 are as follows: For the year ending December 31, 2021 $ 24,792 2022 $ 25,572 2023 $ 8,612 Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes
Note 14 - Subsequent Events	Note 14 – Subsequent events On January 22, 2021, we issued 4,800 On February 3, 2021, we issued 1,500,000 shares of common stock, valued at $0.029 per share, for consulting services. On February 9, 2021, we issued 300,752 shares of common stock, valued at $0.0665 per share, for an investment in the Company’s Private Placement. On February 15, 2021, we issued 1,000,000 shares of common stock, valued at $0.05 per share, for an investment in the Company’s Private Placement. On February 16, 2021, we issued 147,058 shares of common stock, valued at $0.068 per share, for an investment in the Company’s Private Placement. On February 17, 2021, we issued 1,000,000 shares of common stock, valued at $0.129 per share, for consulting services. On February 19, 2021, we issued 681,818 shares of common stock, valued at $0.055 per share, for an investment in the Company’s Private Placement. On March 25, 2021, we issued 1,282,051 shares of common stock, valued at $0.078 per share, for an investment in the Company’s Private Placement. In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2020 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and significant accounting policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Basis of Presentatio_3

Note 2 - Basis of Presentation and significant accounting policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) 2) 3) 4) 5) ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.

Note 2 - Basis of Presentatio_4

Note 2 - Basis of Presentation and significant accounting policies: Wholesale policies (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Wholesale policies	Wholesale policies: Delivery. Purchase Price & Payments. Inspection of Goods & Rejection. Risk of Loss.

Note 2 - Basis of Presentatio_5

Note 2 - Basis of Presentation and significant accounting policies: Retail policies of e-commerce (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Retail policies of e-commerce	Retail policies of e-commerce: Returns. Shipping. Out of Stock.

Note 2 - Basis of Presentatio_6

Note 2 - Basis of Presentation and significant accounting policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. $250,000 cash deposited in the financial institution as of the balance sheet date is insured by the Federal Deposit Insurance Corporation (FDIC) and the amount not insured is $12,147, there isn’t any losses recorded as of December 31, 2020.

Note 2 - Basis of Presentatio_7

Note 2 - Basis of Presentation and significant accounting policies: Inventories (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.

Note 2 - Basis of Presentatio_8

Note 2 - Basis of Presentation and significant accounting policies: Derivative Liabilities (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $437,549 and $521,700 at December 31, 2020 and 2019, respectively.

Note 2 - Basis of Presentatio_9

Note 2 - Basis of Presentation and significant accounting policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Note 2 - Basis of Presentati_10

Note 2 - Basis of Presentation and significant accounting policies: Depreciation and Amortization (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2020 and 2019 was $389 and $0, respectively.

Note 2 - Basis of Presentati_11

Note 2 - Basis of Presentation and significant accounting policies: Intangible Assets (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2020 and 2019 was $6,591 and $6,591, respectively.

Note 2 - Basis of Presentati_12

Note 2 - Basis of Presentation and significant accounting policies: Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

Note 2 - Basis of Presentati_13

Note 2 - Basis of Presentation and significant accounting policies: Research and Development (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $561,990 and $27,685 for the years ended December 31, 2020 and 2019, respectively.

Note 2 - Basis of Presentati_14

Note 2 - Basis of Presentation and significant accounting policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”

Note 2 - Basis of Presentati_15

Note 2 - Basis of Presentation and significant accounting policies: Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements.

Note 2 - Basis of Presentati_16

Note 2 - Basis of Presentation and significant accounting policies: Leases (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $58,976 as of December 31, 2020. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2020 and 2019, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2020 and 2019: Balance, December 31 $ 466,612 Issuance of new derivative liabilities 602,934 Conversions to paid-in capital (498,325) Change in fair market value of derivative liabilities (49,521) Balance, December 31, 2019 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270) Change in fair market value of derivative liabilities (206,501) Balance, December 31, 2020 $ 437,549

Note 2 - Basis of Presentati_17

Note 2 - Basis of Presentation and significant accounting policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

Note 2 - Basis of Presentati_18

Note 2 - Basis of Presentation and significant accounting policies: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

Note 2 - Basis of Presentati_19

Note 2 - Basis of Presentation and significant accounting policies: Net Loss Per Share (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2020 and 2019, a total of 579,347,525 and 181,588,903 ,

Note 2 - Basis of Presentati_20

Note 2 - Basis of Presentation and significant accounting policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2020
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Note 2 - Basis of Presentati_21

Note 2 - Basis of Presentation and significant accounting policies: Leases: Schedule of change in derivative liability (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of change in derivative liability	Balance, December 31 $ 466,612 Issuance of new derivative liabilities 602,934 Conversions to paid-in capital (498,325) Change in fair market value of derivative liabilities (49,521) Balance, December 31, 2019 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270) Change in fair market value of derivative liabilities (206,501) Balance, December 31, 2020 $ 437,549

Note 4 - Prepaid expense and _2

Note 4 - Prepaid expense and other current assets: Schedule of Prepaid expenses and other current assets (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of Prepaid expenses and other current assets	December 31, 2020 December 31, 2019 Prepaid consulting $ 76,663 $ 88,261 Insurance 665 - Prepaid costs - 1,118 Total $ 77,328 $ 89,379

Note 5 - Fixed assets_ Property

Note 5 - Fixed assets: Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Property, Plant and Equipment	December 31, 2020 December 31, 2019 Computer hardware $ 10,747 $ 10,747 Office furniture and equipment 3,639 3,639 Shipping and other equipment 7,023 1,575 Total 21,409 15,961 Accumulated depreciation (16,350) (15,961) Property and equipment, net $ 5,059 $ -

Note 6 - Other Assets_ Schedule

Note 6 - Other Assets: Schedule of Other Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of Other Assets	December 31, 2020 December 31, 2019 Prepaid consulting $ 39,914 $ 20,238 Deposit 11,638 4,123 Licenses, net 140,370 146,961 Total $ 191,922 $ 171,322

Note 6 - Other Assets_ Schedu_2

Note 6 - Other Assets: Schedule of net licenses (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of net licenses	December 31, 2020 December 31, 2019 License $ 153,552 $ 153,552 Accumulated amortization (13,182) (6.591) Licenses, net $ 140,370 $ 146,961

Note 8 - Notes Payable - Rela_2

Note 8 - Notes Payable - Related Parties: Notes payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Notes payable, Related Parties	December 31, 2020 December 31, 2019 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 $ 7,054 $ 18,162 Two notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019 26,064 37,671 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,646 534,700 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 112,000 105,600 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004,respectively, with maturity date of April 20, 2019 264,334 246,334 944,098 942,467 Less debt discount - (4,939) $ 944,098 $ 937,528

Note 10 - Income Taxes_ Schedul

Note 10 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	December 31, 2020 December 31, 2019 Expected income tax at statutory rate $ (458,619) $ (356,438) State tax 168 168 Permanent differences 295,578 220,501 Other (336) 6,556 Change in valuation allowance 163,209 129,213 Provision for income taxes $ - $ -

Note 10 - Income Taxes_ Sched_2

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	December 31, 2020 December 31, 2019 Net operating loss carry-forward $ 1,668,324 $ 1,450,896 Valuation allowance (1,668,324) (1,450,896) Net deferred tax asset $ - $ -

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Tables)	12 Months Ended
	Dec. 31, 2020
Tables/Schedules
Schedule of Future Minimum Lease Payments	For the year ending December 31, 2021 $ 24,792 2022 $ 25,572 2023 $ 8,612

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details)	12 Months Ended
	Dec. 31, 2020
Details
Entity Incorporation, Date of Incorporation	Aug. 6, 2007
Entity Incorporation, State or Country Code	NV

Note 2 - Basis of Presentati_22

Note 2 - Basis of Presentation and significant accounting policies: Derivative Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
Derivative Liability, Current	$ 437,549	$ 521,700

Note 2 - Basis of Presentati_23

Note 2 - Basis of Presentation and significant accounting policies: Depreciation and Amortization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Details
Depreciation	$ 389	$ 0

Note 2 - Basis of Presentati_24

Note 2 - Basis of Presentation and significant accounting policies: Net Loss Per Share (Details) - shares	Dec. 31, 2020	Dec. 31, 2019
Details
Antidilutive Common Shares Excluded from EPS calculation	579,347,525	181,588,903

Note 3 - Restricted Cash (Detai

Note 3 - Restricted Cash (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Details
Restricted Cash, Current	$ 10,000
Restricted Cash, Current, Nature of Restriction, Description	used as collateral for a Company credit card

Note 4 - Prepaid expense and _3

Note 4 - Prepaid expense and other current assets: Schedule of Prepaid expenses and other current assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
Prepaid Consulting	$ 76,663	$ 88,261
Insurance	665	0
Prepaid costs	0	1,118
Prepaid expenses and other current assets	$ 77,328	$ 89,379

Note 5 - Fixed assets_ Proper_2

Note 5 - Fixed assets: Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Computer Equipment
Property, Plant and Equipment, Gross	$ 10,747	$ 10,747
Office Equipment
Property, Plant and Equipment, Gross	3,639	3,639
Other Transportation Equipment
Property, Plant and Equipment, Gross	7,023	1,575
Property, Plant and Equipment, Gross	21,409	15,961
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(16,350)	(15,961)
Property and equipment, net	$ 5,059	$ 0

Note 5 - Fixed assets (Details)

Note 5 - Fixed assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Details
Depreciation	$ 389	$ 0

Note 6 - Other Assets_ Schedu_3

Note 6 - Other Assets: Schedule of Other Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
Prepaid Consulting	$ 39,914	$ 20,238
Deposit	11,638	4,123
Licenses, net	140,370	146,961
Assets, Noncurrent	$ 191,922	$ 171,322

Note 6 - Other Assets_ Schedu_4

Note 6 - Other Assets: Schedule of net licenses (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
License	$ 153,552	$ 153,552
Accumulated amortization	(13,182)	(6.591)
Licenses, net	$ 140,370	$ 146,961

Note 8 - Notes Payable - Rela_3

Note 8 - Notes Payable - Related Parties: Notes payable, Related Parties (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Note payable - Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2018
Long-term Debt, Gross	$ 7,054	$ 18,162
Two notes payable - Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019
Long-term Debt, Gross	26,064	37,671
One note payable - Chief Executive Officer, unsecured, no interest, paid from a % of revenues
Long-term Debt, Gross	534,646	534,700
Note payable - Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2018,
Long-term Debt, Gross	112,000	105,600
Two notes payable - Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2018
Long-term Debt, Gross	264,334	246,334
Long-term Debt, Gross	944,098	942,467
Less debt discount	0	(4,939)
Long-term Debt, Net	$ 944,098	$ 937,528

Note 9 - Related party transa_2

Note 9 - Related party transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Related Parties Transaction #1
Sale of Stock, Transaction Date	Dec. 12, 2019
Stock Issued During Period, Shares, New Issues	100,000,000
Sale of Stock, Price Per Share	$ 0.0013
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #2
Sale of Stock, Transaction Date	Jun. 4, 2020
Stock Issued During Period, Shares, New Issues	70,000,000
Sale of Stock, Price Per Share	$ 0.023
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #3
Sale of Stock, Transaction Date	Jun. 9, 2020
Stock Issued During Period, Shares, New Issues	18,181,818
Sale of Stock, Description of Transaction	for the complete conversion of $60,000 for convertible note
Stock Issued	$ 60,000
Related Parties Transaction #4
Sale of Stock, Transaction Date	Jun. 11, 2020
Stock Issued During Period, Shares, New Issues	40,000,000
Sale of Stock, Price Per Share	$ 0.0046
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #5
Sale of Stock, Transaction Date	Jun. 15, 2020
Stock Issued During Period, Shares, New Issues	3,000,000
Sale of Stock, Price Per Share	$ 0.0017
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #6
Sale of Stock, Transaction Date	Jun. 15, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Sale of Stock, Price Per Share	$ 0.0023
Sale of Stock, Description of Transaction	to the medical officer for consulting services
Related Parties Transaction #7
Sale of Stock, Transaction Date	Jun. 25, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Sale of Stock, Price Per Share	$ 0.0083
Sale of Stock, Description of Transaction	to the medical officer for consulting services
Related Parties Transaction #8
Sale of Stock, Transaction Date	Jul. 17, 2020
Stock Issued During Period, Shares, New Issues	7,500,000
Sale of Stock, Price Per Share	$ 0.0064
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #9
Sale of Stock, Transaction Date	Jul. 31, 2020
Stock Issued During Period, Shares, New Issues	12,000,000
Sale of Stock, Price Per Share	$ 77
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #10
Sale of Stock, Transaction Date	Oct. 1, 2020
Stock Issued During Period, Shares, New Issues	15,000,000
Sale of Stock, Price Per Share	$ 0.0071
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #11
Sale of Stock, Transaction Date	Oct. 5, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Sale of Stock, Price Per Share	$ 0.0086
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #12
Sale of Stock, Transaction Date	Dec. 17, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Sale of Stock, Price Per Share	$ 0.0067
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Related Parties Transaction #13
Sale of Stock, Transaction Date	Dec. 30, 2020
Stock Issued During Period, Shares, New Issues	6,000,000
Sale of Stock, Price Per Share	$ 0.006
Sale of Stock, Description of Transaction	under a Restricted Stock Award
Sale of Stock Transaction 1
Accrued salaries	$ 524,034	$ 663,100
Stock Issued During Period, Shares, New Issues		72,033,333
Sale of Stock, Description of Transaction		for an investment in the Company’s Private Placement
Stock Issued		$ 76,430

Note 10 - Income Taxes_ Sched_3

Note 10 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
Expected income tax at statutory rate	$ (458,619)	$ (356,438)
State Tax	168	168
Permanent differences	295,578	220,501
Other	(336)	6,556
Change in valuation allowance	163,209	129,213
Provision for income taxes	$ 0	$ 0

Note 10 - Income Taxes_ Sched_4

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Details
Net operating loss carry-forward	$ 1,668,324	$ 1,450,896
Valuation allowance	(1,668,324)	(1,450,896)
Net deferred tax asset	$ 0	$ 0

Note 11 - Equity (Details)

Note 11 - Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Common Stock, Shares Authorized	3,500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Shares, Issued	2,233,741,391	1,614,627,811
Common Stock, Shares, Outstanding	2,233,741,391	1,614,627,811
Preferred Stock, Shares Issued	0
Preferred Stock, Shares Outstanding	0
Sale of Stock Transaction 1
Stock Issued During Period, Shares, New Issues		72,033,333
Sale of Stock, Description of Transaction		for an investment in the Company’s Private Placement
Stock Issued		$ 76,430
Sale of Stock Transaction 2
Stock Issued During Period, Shares, New Issues		200,000,000
Sale of Stock, Description of Transaction		for consulting services
Stock Issued		$ 468,000
Sale of Stock Transaction 3
Stock Issued During Period, Shares, New Issues		95,970,000
Sale of Stock, Description of Transaction		for a licesnse
Stock Issued		$ 153,552
Sale of Stock Transaction 4
Stock Issued During Period, Shares, New Issues		235,561,296
Sale of Stock, Description of Transaction		for the conversion of convertible notes
Stock Issued		$ 762,264
Sale of Stock Transaction 5
Stock Issued During Period, Shares, New Issues	192,375,737
Sale of Stock, Description of Transaction	for an investment in the Company’s Private Placement
Stock Issued	$ 607,500
Sale of Stock Transaction 6
Stock Issued During Period, Shares, New Issues	173,500,000
Sale of Stock, Description of Transaction	for consulting services
Stock Issued	$ 669,750
Sale of Stock Transaction 7
Stock Issued During Period, Shares, New Issues	78,681,818
Sale of Stock, Description of Transaction	for salaries
Stock Issued	$ 495,900
Sale of Stock Transaction 8
Stock Issued During Period, Shares, New Issues	174,556,025
Sale of Stock, Description of Transaction	for the conversion of convertible notes
Stock Issued	$ 703,152

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Details
Payments for Rent	$ 25,993	$ 22,494

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2020USD ($)
Details
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 24,792
Operating Leases, Future Minimum Payments, Due in Two Years	25,572
Operating Leases, Future Minimum Payments, Due in Three Years	$ 8,612

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details)	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Event 1
Subsequent Event, Date	Jan. 22, 2021
Sale of Stock, Transaction Date	Jan. 22, 2021
Subsequent Event, Description	we issued 4,800,000 shares of common stock
Stock Issued During Period, Shares, New Issues	4,800,000
Stock Issued | $	$ 60,000
Event 2
Subsequent Event, Date	Feb. 3, 2021
Sale of Stock, Transaction Date	Feb. 3, 2021
Subsequent Event, Description	we issued 1,500,000 shares of common stock
Stock Issued During Period, Shares, New Issues	1,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.029
Event 3
Subsequent Event, Date	Feb. 9, 2021
Sale of Stock, Transaction Date	Feb. 9, 2021
Subsequent Event, Description	we issued 300,752 shares of common stock
Stock Issued During Period, Shares, New Issues	300,752
Sale of Stock, Price Per Share | $ / shares	$ 0.0665
Event 4
Subsequent Event, Date	Feb. 15, 2021
Sale of Stock, Transaction Date	Feb. 15, 2021
Subsequent Event, Description	we issued 1,000,000 shares of common stock
Stock Issued During Period, Shares, New Issues	1,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.05
Event 5
Subsequent Event, Date	Feb. 16, 2021
Sale of Stock, Transaction Date	Feb. 16, 2021
Subsequent Event, Description	we issued 147,058 shares of common stock
Stock Issued During Period, Shares, New Issues	147,058
Sale of Stock, Price Per Share | $ / shares	$ 0.068
Event 6
Subsequent Event, Date	Feb. 17, 2021
Sale of Stock, Transaction Date	Feb. 17, 2021
Subsequent Event, Description	we issued 1,000,000 shares of common stock
Stock Issued During Period, Shares, New Issues	1,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.129
Event 7
Subsequent Event, Date	Feb. 19, 2021
Sale of Stock, Transaction Date	Feb. 19, 2021
Subsequent Event, Description	we issued 681,818 shares of common stock
Stock Issued During Period, Shares, New Issues	681,818
Sale of Stock, Price Per Share | $ / shares	$ 0.055
Event 8
Subsequent Event, Date	Mar. 25, 2021
Sale of Stock, Transaction Date	Mar. 25, 2021
Subsequent Event, Description	we issued 1,282,051 shares of common stock
Stock Issued During Period, Shares, New Issues	1,282,051
Sale of Stock, Price Per Share | $ / shares	$ 0.078